Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

41.69 +0.95 (+2.33%)
Official Closing Price Updated: 4:15 PM EST, Mar 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
News headline image
2 Biotech Stocks to Buy Hand Over Fist in December ↗
Via The Motley Fool
News headline image
End Of Year Rally: 3 Stocks To Watch (InterDigital, Futu Holdings, Exelixis) ↗
As the calendar winds down, the stock market often heats up. This 
Via Talk Markets
Topics Stocks / Equities
News headline image
Ten Young Ones ↗
Here are a variety of lesser-known charts from my “Recents” watch list. Quite a few of them look like good bullish plays. 
Via Talk Markets
Topics Stocks / Equities
News headline image
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals. ↗
EXELIXIS INC (NASDAQ:EXEL): good value for what you're paying. 
Via Chartmill
News headline image
Earnings Preview: Exelixis ↗
 
Via Benzinga
News headline image
1 No-Brainer Stock to Buy With $40 ↗
The midcap biotech just became an even better buy. 
Via The Motley Fool
News headline image
Analyst Ratings For Exelixis ↗
 
Via Benzinga
News headline image
Navigating 16 Analyst Ratings For Exelixis ↗
 
Via Benzinga
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
From Exelixis, Inc.
Via Business Wire
News headline image
BioNTech Stock Got A IBD RS Rating Lift ↗
A Relative Strength Rating upgrade for BioNTech ADR shows improving technical performance. 
Via Investor's Business Daily
News headline image
Key Takeaways From Exelixis Analyst Ratings ↗
 
Via Benzinga
News headline image
Vericel Stock Sees RS Rating Shoot Higher ↗
The Relative Strength (RS) Rating for Vericel stock entered a higher percentile Monday, as it got a lift from 69 to 79. 
Via Investor's Business Daily
News headline image
NASDAQ:EXEL is an undervalued gem with solid fundamentals. ↗
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
From Exelixis, Inc.
Via Business Wire
News headline image
3 Magnificent Stocks Under $100 to Buy in November ↗
The price could be right for these stocks. 
Via The Motley Fool
News headline image
Reddit, Roblox And Garmin Are Among Top 10 Large Cap Gainers Last Week (Oct 28-Nov 1): Are The Others In Your Portfolio? ↗
The top 10 performers last week were Reddit, Paycom, Mobileye, Exelixis, Garmin, Roblox, Twilio, Snap, Waters, and Atlassian. Many analysts raised price forecasts. 
Via Benzinga
News headline image
Snap Posts Upbeat Earnings, Joins Unisys, AtriCure, Garmin And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Exelixis (EXEL) Q3 2024 Earnings Call Transcript ↗
EXEL earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Biotech Momentum Trades For The Q4 Rally ↗
The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
Via Talk Markets
News headline image
Momentum Has Narrowed Again, Significantly ↗
It is more of a stock pickers market than usual as momentum factors are currently exaggerated. 
Via Talk Markets
News headline image
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals. ↗
In a market where value is scarce, EXELIXIS INC (NASDAQ:EXEL) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
News headline image
Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
From Exelixis, Inc.
Via Business Wire
News headline image
Blue Skies, New Highs Remain Disciplined And Do Not Chase Extended Ideas ↗
It is Fall clean up time. Sell lagging and sagging companies. 
Via Talk Markets
News headline image
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals. ↗
For those who appreciate value investing, EXELIXIS INC (NASDAQ:EXEL) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
2 Growth Stocks to Buy With Less Than $100 ↗
No need to break the bank to get in on these likely long-term winners. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.